The proven benefits of angiotensin-converting enzyme (ACE) inhibitors in the management of congestive heart failure, hypertension, and diabetes mellitus-related cardiovascular and renal complications have led to a tremendous increase in their use in the past decade. As such, adverse effects of ACE inhibitors are increasingly being recognized and reported. Cough, the most common side effect of ACE inhibitor therapy, occurs in 5% to 20% of patients and is more common in women than in men. Angioedema, a potentially life-threatening complication, occurs in 0.1% to 0.2% of patients receiving ACE inhibitors, with 60% of cases presenting within the first week. The incidence of angioedema is fivefold higher in black people, but is independent of age and dose of ACE inhibitor. The typical presentation of angioedema involves swelling of the facial and/or oropharyngeal tissue with occasional dermatological manifestations.